Company intelligence / Profile preview
Equilibra Bioscience LLC
- Ownership
- Private
- Development stage
- Other
Overview
SR-604, their lead candidate, is in Phase I clinical trials for Hemophilia A. According to GlobalData, Phase I drugs for Hemophilia A have a 97% phase transition success rate for progressing into Phase II[2].
- Therapeutic areas
- Hematology
- Modalities
- Monoclonal antibody
- Industry
- Biotech
Drug pipeline
1 assetBeyond the preview
Go deeper on Equilibra Bioscience LLC.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Equilibra Bioscience LLC.